Precigen Inc. (PGEN) Presents Preclinical Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500 ends down as oil tops $100 per barrel
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Rogers adds Sportsnet+ content to Xfinity TV packages for free
- White House copper tariff plan stalls amid affordability concerns, sources say
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Precigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T® with Intrinsic PD-1 Blockade at the AACR Annual Meeting 2023
April 17, 2023 9:01 AM EDTFirst preclinical data presented for the next generation of the UltraCAR-T platform utilizing a mesothelin (MSLN) chimeric antigen receptor (CAR)
MSLN is overexpressed on multiple solid tumors such as mesothelioma, ovarian cancer and pancreatic cancer
Proprietary technology for checkpoint blockade intrinsic to UltraCAR-T cells has the potential for an improved safety profile and reduced cost by eliminating the need for checkpoint inhibitor combinationÂ
Single administration of next generation MSLN UltraCAR-T incorporating intrinsic PD-1 blockade resulted in robust UltraCAR-T cell expansion and durable persistence leading to... More
